Acupuncture induced immunoregulatory influence on the clinical state of patients suffering from chronic spastic bronchitis and undergoing long-term treatment with corticosteroids. 1989

J Sliwinski, and M Kulej
Specialistic Clinic for Outpatients, Allergy and Immunodeficiency Syndromeul, Warsaw, Poland.

36 patients suffering from chronic spastic bronchitis were treated with acupuncture. The patient group consisted of 13 men and 23 women varying in age from 26 to 64 years, with an average age of 42.2 years. The therapy consisted of two or three months of acupuncture treatment in alternation with an equal period (2 or 3 months) of recess during which no treatment was administered. Before acupuncture, patients had taken corticosteroids either orally and/or intramuscularly for a period of 2 to 24 years. For those taking corticosteroids orally the daily dosages ranged from 10 to 40 mg Encorton (Polfa, Poland). The patients took intramuscular injections of 40 to 60 mg Kenalog (Squibb) every three or four weeks. Acupuncture sessions were twice a week. All the patients had 42 acupuncture sessions. Before the treatment all the patients, and 30 healthy volunteers, made leukocytes migration tests [(in vivo, using the Rebuck method (1) as modified by Southam (2)]. It was found that patients suffering from chronic spastic bronchitis have leukocytes migration defect. This defect increases in patients who have taken corticosteroids. We have also found that after 42 acupuncture sessions the amount of leukocytes in the tissue pool comes close to the value found in healthy persons during leukocyte migration, [(tested in vivo, using the Rebuck method as modified by Southam (2)].

UI MeSH Term Description Entries
D007961 Leukocyte Migration-Inhibitory Factors Protein factor(s) released by sensitized lymphocytes (and possibly other cells) that inhibit the movement of LEUKOCYTES, especially polymorphonuclear cells, away from their site of release. Assays for these factors are used as tests for cellular immunity. Two of the common assays are the LEUKOCYTE MIGRATION CAPILLARY TUBE TECHNIQUE (LMCT) and the LEUKOCYTE MIGRATION AGAROSE TEST (LMAT). Migration-Inhibition Factors, Leukocyte,Leukocyte Migration-Inhibition Factors,Migration-Inhibitory Factors, Leukocyte,Factors, Leukocyte Migration-Inhibition,Factors, Leukocyte Migration-Inhibitory,Leukocyte Migration Inhibition Factors,Leukocyte Migration Inhibitory Factors,Migration Inhibition Factors, Leukocyte,Migration Inhibitory Factors, Leukocyte
D008222 Lymphokines Soluble protein factors generated by activated lymphocytes that affect other cells, primarily those involved in cellular immunity. Lymphocyte Mediators,Mediators, Lymphocyte
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001991 Bronchitis Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI. Bronchitides
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J Sliwinski, and M Kulej
October 1966, Deutsche medizinische Wochenschrift (1946),
J Sliwinski, and M Kulej
May 1964, Orvosi hetilap,
J Sliwinski, and M Kulej
November 1964, Wiener medizinische Wochenschrift (1946),
J Sliwinski, and M Kulej
January 1964, Acta tuberculosea et pneumologica Belgica,
J Sliwinski, and M Kulej
January 1967, Beitrage zur Klinik und Erforschung der Tuberkulose und der Lungenkrankheiten,
J Sliwinski, and M Kulej
September 1981, ZFA. Zeitschrift fur Allgemeinmedizin,
Copied contents to your clipboard!